1. "Department of Medicine"
Formats
  1. Journal Article (19347)
  2. Meeting Abstract (15822)
  3. Review (1102)
  4. Book Section (924)
  5. Editorial (580)
  6. Research Letter (301)
  7. Conference Paper (299)
  8. Guidelines (285)
  9. Correspondence (226)
  10. Miscellaneous (87)
  11. Book Whole (61)
Groups
  1. Department of Medicine (39034)
  2. Solid Tumor Oncology Division (22035)
  3. Hematologic Malignancies, Division of (13003)
  4. Center for Hematologic Malignancies (10841)
  5. GSK Faculty (10529)
  6. Survivorship Research (9202)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Sergio Giralt (1050)
  4. Miguel-Angel Perales (913)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (642)
  2. 2024 (2141)
  3. 2023 (2451)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2560)

More Years

Publications
  1. Journal of Clinical Oncology (6050)
  2. Blood (3572)
  3. Annals of Oncology (1395)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (890)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6364)
  2. Elsevier Inc. (4610)
  3. American Society of Hematology (3843)
  4. American Association for Cancer Research (2879)
  5. Oxford University Press (2271)
  6. Nature Publishing Group (2080)

More Publishers

Results (39034)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • DNA methylation-based Burkitt Lymphoma epitypes have distinct molecular and clinical features
    Meeting Abstract

    Thomas, N.; Dreval, K.; Gerhard, D. S.; Hilton, L. K.; Abramson, J. S.; Bartlett, N. L.; Bethony, J.; Bowen, J.; Bryan, A.; Casper, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Population pharmacokinetic model identifies an optimal fludarabine exposure for improved outcomes after CD19-directed CAR T cell therapy for aggressive B-NHL: Analysis from the Cell Therapy Consortium
    Meeting Abstract

    Scordo, M.; Flynn, J. R.; Devlin, S. M.; Gonen, M.; Parascondola, A.; Tomas, A. A.; Shouval, R.; Brower, J.; Porter, D. L.; Schuster, S. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Real-world outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: Subgroup analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry
    Meeting Abstract

    Landsburg, D. J.; Frigault, M.; Heim, M.; Foley, S. R.; Hill, B. T.; Ho, C. M.; Jacobson, C. A.; Jaglowski, S.; Locke, F. L.; Ram, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes of subsequent anti-lymphoma therapies in patients (pts) with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) or standard of care (SOC) in the second-line (2L) ZUMA-7 study
    Meeting Abstract

    Ghobadi, A.; Munoz, J.; Westin, J.; Locke, F. L.; Miklos, D. B.; Rapoport, A. P.; Perales, M. A.; Reagan, P. M.; McGuirk, J. P.; Jacobson, C. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Individualized treatment-adjusted risk stratification in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A. R.; Derkach, A.; Ziccheddu, B.; Weinhold, N.; Maclachlan, K. H.; Diamond, B.; Davies, F. E.; Boyle, E.; Walker, B. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tracking the earliest genomic events in multiple myeloma life-history
    Meeting Abstract

    Cirrincione, A.; Ziccheddu, B.; Maclachlan, K. H.; Poos, A. M.; Chojnacka, M.; Diamond, B.; Boyle, E. M.; Blaney, P.; Gagler, D.; Zhang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical benefit associated with biomarker changes indicative of disease modification in patients with myelofibrosis treated with the BET inhibitor pelabresib as monotherapy or in combination with ruxolitinib
    Meeting Abstract

    Scandura, J.; Verstovsek, S.; Kremyanskaya, M.; Talpaz, M.; Rampal, R. K.; Vannucchi, A.; Gupta, V.; Palandri, F.; Patriarca, A.; Bose, P.; more...
    Blood (2022)

    Fulltext@MSK | Save